Full-Time
Posted on 7/14/2026
Pharmaceutical company developing medicines and vaccines
$190.8k - $300.3k/yr
No H1B Sponsorship
North Wales, PA, USA + 1 more
More locations: Linden, NJ, USA
Hybrid
Hybrid role; on-site required in North Wales, PA and Rahway, NJ.
Bachelor's, MBA
See people who can refer or advise you
Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.
Company Size
10,001+
Company Stage
IPO
Headquarters
Kenilworth, Illinois
Founded
1891
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Hybrid Work Options
Merck's $10.8B Prometheus deal delivers another win - plus a Phase 2b miss. August 4, 2026 | The anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside second-quarter earnings. Merck has recorded a loss and a win for the experimental anti-TL1A antibody it picked up in its nearly $11 billion immunology buyout of Prometheus Biosciences a few years back. The asset, a monoclonal antibody known as tulisokibart, failed to meet the main goal of a Phase 2 trial for patients with systemic sclerosis-associated interstitial lung disease (SSC ILD), according to Merck's second-quarter earnings release shared Tuesday. The miss has prompted the New Jersey-based pharma to discontinue the study. Merck didn't share data behind the fail but said no new safety concerns were identified. The study enrolled 154 patients and lists three safety measures and one efficacy goal as primary endpoints. The Big Pharma also reported a win for tulisokibart in a skin condition called hidradenitis suppurativa (HS), announcing that the Phase 2b trial met its primary and key secondary endpoints. Merck was mum on the details but said it would share the full results at an upcoming medical conference. The study enrolled 147 patients and measured the percentage of participants with an over 50% reduction in skin abscesses and inflammatory nodules. Merck picked up tulisokibart in 2023 when it acquired Prometheus for $10.8 billion. Also known as MK-7240, tulisokibart was the centerpiece of the deal, with its main promise expected as treatment for of ulcerative colitis (UC) and Crohn's disease. Given its intravenous route of administration, Merck's tulisokibart will likely "need to be meaningfully improved" over Roche's afimkibart, which can be given subcutaneously, BMO Capital Markets analysts said. Both assets are being tested for ulcerative colitis. June 23, 2026 Earlier this summer, Merck reported a Phase 3 victory for tulisokibart in UC, sharing that the anti-TL1A antibody helped patients achieve clinical remission, without revealing any data. Given the lack of information, analysts remained cautious about the asset's prospects, also citing potential competitive overhangs. For example, Roche picked up the anti-TL1A antibody afimkibart in its $7.1 billion Telavant acquisition in 2023. "With Merck's tulisokibart administered by IV and Roche's afimkibart administered subcutaneously in the induction setting, tulisokibart's efficacy would likely need to be meaningfully improved vs. afimkibart to be competitive and support strong preferential uptake if approved," BMO analysts wrote in June. Merck is also developing a subcutaneous formulation of tulisokibart for maintenance treatment, which BMO noted "could help lessen such headwinds to uptake." "We look forward to the upcoming readout of the larger induction and maintenance study, which, together with the induction-only study, would form the basis of a regulatory filing and will be presented at an upcoming scientific congress," Merck R&D head Dean Li said on an Aug. 4 investor call. He added that the UC late-stage results "reinforce the potential of targeting TL1A to help address immunofibrosis, a key driver of disease progression across multiple immune-mediated inflammatory conditions." Li framed the Phase 2 studies as an exploration of the anti-TL1A hypothesis, citing a broad development program across radiographic axial spondyloarthritis, psoriatic arthritis and rheumatoid arthritis. "The positive readout for HS gives us more confidence in the derm possibilities for this drug, and so that's where we're looking at," Li said on the call's Q&A portion. When pressed on the failure in SSC ILD, he said, "I would just step back. I don't know any anti-cytokine that has worked. So, this was a bold move to move that forward. It's a challenging and refractory disease." Merck's once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options. July 16, 2026 A narrow beat. Overall, it was a clean quarter with key launches demonstrating traction, according to a Tuesday note from BMO analysts. Merck reported $16.6 billion in sales, up from the expected consensus estimate of $16.37 billion. The pharma also narrowed and raised its sales guidance for the 2026 fiscal year to a midpoint of $66.8 billion, up slightly from $66.4 billion. Earnings per share (EPS) estimates narrowed to $2.66-$2.76, taking into account a hefty negative impact related to the $6.7 billion Terns buyout that closed in the second quarter. The pharma had previously expected its 2026 EPS to range from $5.04 to $5.16. Merck's beats stemmed from faster-than-expected conversions to Keytruda Qlex, the subcutaneous formulation of the blockbuster cancer therapy traditionally delivered intravenously. A 20% beat over consensus estimates for oncology product Welireg gave Merck an additional boost. Chronic obstructive pulmonary disease med Ohtuvayre also served as "a bright spot," up 19%, according to Guggenheim analysts. Meanwhile, newly approved Enflonsia for RSV fell short of consensus estimates by 84%, but BMO analysts said the launch was still early and "initial revenue lumpiness is expected." Merck's acquisition of Terns Pharmaceuticals follows other big-ticket purchases, including of Verona Pharma and Cidara Therapeutics, as the pharma prepares for the impending expiration of its blockbuster's patents. March 25, 2026
Merck raised its 2026 revenue forecast to between $66.3 billion and $67.3 billion, up from a previous range of $65.8 billion to $67 billion. However, the company cut its adjusted earnings outlook to $2.66 to $2.76 per share, down from $5.04 to $5.16, due to one-time charges totalling $14.7 billion related to acquisitions of Terns and Cidara Therapeutics. For the second quarter, Merck reported $16.61 billion in revenue, up 5% year-over-year. Keytruda generated $8.37 billion in sales, whilst newer drugs showed strong growth. Winrevair sales reached $588 million, up 75%, and Capvaxive posted $184 million, up 42%. The company is acquiring businesses to offset upcoming generic competition for several drugs, including Keytruda in 2028.
Merck (MRK) earnings Q2 2026. Merck & Co. announced strong second-quarter results while updating its revenue outlook as new products have demonstrated significant growth. The pharmaceutical company raised its 2026 revenue forecast to between $66.3 billion and $67.3 billion, up from a prior range of $65.8 billion to $67 billion. However, Merck lowered its profit guidance following a $5.7 billion charge related to its acquisition of Terns Pharmaceuticals. The projected adjusted earnings per share are now expected to be between $2.66 and $2.76, reflecting this one-time charge and a $9 billion impairment linked to the acquisition of Cidara Therapeutics earlier this year. This adjustment brings the previous earnings estimate down from a range of $5.04 to $5.16 per share. Merck's net loss for the quarter amounted to $1.34 billion, equivalent to 54 cents per share, compared to a net income of $4.43 billion, or $1.76 per share, during the same period last year. Notably, revenue for the quarter reached $16.61 billion, marking a 5% increase year-over-year. Sales of the immunotherapy drug Keytruda were noteworthy, generating $8.37 billion in the second quarter, which exceeded analyst expectations. Additionally, Merck's newer products, including Winrevair and the pneumococcal vaccine Capvaxive, showed promising sales growth. Merck's animal health division also performed well, generating $1.78 billion in sales, which surpassed estimates. Why this story matters Key takeaway Opposing viewpoint
Merck is set to announce its Q2 earnings on Tuesday before market hours. The market expects revenue to grow 3% year-on-year, reversing the 1.9% decrease recorded in the same quarter last year. Last quarter, Merck reported revenues of $16.29 billion, up 4.9% year-on-year, beating analysts' expectations. The company also exceeded EPS estimates. Analysts have generally reconfirmed their estimates over the last 30 days. Among peers, Corcept reported 7.3% revenue growth but missed estimates by 1%, whilst Bristol-Myers Squibb posted 5.7% growth, topping estimates by 12.9%. Merck's share price has risen 2.6% over the past month, with an average analyst price target of $135.19 compared to the current share price of $130.31.
StockStory analysed three cash-producing stocks, recommending investors avoid two while highlighting one with stronger prospects. Allegro MicroSystems faces end-market challenges, with flat sales over two years and operating margin falling to 2% over five years. The power management chip designer trades at 37.6x forward P/E. Viavi Solutions showed weak performance with 3.4% annual growth over five years, whilst earnings per share remained flat despite revenue growth. The telecommunications testing company trades at 26.2x forward P/E. Merck emerged as the recommended stock, boasting a 21.5% trailing 12-month free cash flow margin. The pharmaceutical company's portfolio includes the blockbuster cancer immunotherapy Keytruda. The analysis emphasises that strong cash flow alone doesn't guarantee superior returns without efficient capital allocation.